Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Update

Check-Cap Ltd. (NASDAQ:CHEK) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 9,900 shares, a growth of 7.6% from the November 30th total of 9,200 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 690,100 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Check-Cap in a report on Friday, December 27th. They set a “sell” rating for the company.

Check-Cap Stock Down 2.5 %

NASDAQ CHEK traded down $0.02 on Thursday, hitting $0.97. 19,548 shares of the stock were exchanged, compared to its average volume of 257,456. The company has a 50-day moving average price of $0.94 and a 200-day moving average price of $1.51. The company has a market cap of $5.65 million, a PE ratio of -0.32 and a beta of 0.25. Check-Cap has a fifty-two week low of $0.56 and a fifty-two week high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.